metaboliq
GLP-1 and GLP-2, short for glucagon-like peptide-1 and -2, are separate hormones that your gut cuts from one parent protein, proglucagon, and releases together after a meal. GLP-1 raises insulin when sugar climbs, slows the stomach and turns hunger down. GLP-2 stays mostly in the gut and keeps the lining of the small intestine growing and absorbing food. Rekha, 46, is a bank manager in Indore. Her sister-in-law is on a GLP-1-based treatment, and a cousin has since forwarded a reel calling GLP-2 "the next big thing". Rekha wanted to know which is which. She is a composite of readers who ask this, not a patient.
For appetite and blood sugar, GLP-1 is the one to know about. When GLP-2 has been tested in people, hunger, food intake and stomach emptying stayed the same as on placebo. Its clinical use is narrow: helping people who have lost much of their small bowel absorb more food.
What are GLP-1 and GLP-2, and where do they come from?
Start with where they are made. Scattered through the lining of the lower small intestine and colon are L-cells. Each one builds a long protein called proglucagon and then snips it into pieces,. Two of those pieces are GLP-1 and GLP-2. GLP-2 is 33 amino acids long; GLP-1 is a few shorter.
The pancreas reads the same gene and cuts the protein differently. Its main piece is glucagon, the hormone that raises blood sugar between meals, and that is where the name "glucagon-like peptide" comes from. Drucker, Habener and Holst, who did much of the early work, tell the story in a 2017 review.
Since they leave the same cell together, the two hormones rise together too. When lunch reaches the lower gut, both climb in the blood within the hour. Each then acts through its own receptor. GLP-1 receptors sit in the pancreas, the stomach and the brain, among other places. GLP-2 receptors are mostly in the gut wall. Gasbjerg and colleagues mapped them organ by organ in a 2026 review. Most of the differences below start from that map.
What does GLP-1 do that GLP-2 does not?
Picture the hour after a Sunday lunch of rajma-chawal. Sugar from the rice is climbing, and GLP-1 is one reason it does not climb higher. It tells the pancreas to release extra insulin, but only while sugar is up, which is why it is called an incretin. It holds back glucagon. It slows the stomach, so food trickles into the gut instead of arriving in one rush. It also reaches the brain and dulls the pull towards a second helping.
That last effect has been measured. Verdich and colleagues pooled the raw data from 115 volunteers given GLP-1 through a drip before a free meal. They ate about 12% less than on a saline day, roughly 170 calories. Lean and heavier volunteers cut back by a similar share.
Flint and colleagues checked whether the amount your own gut makes after a meal is enough to matter. In 18 men living with obesity, it was. Hunger ratings fell and the stomach emptied far more slowly. GLP-2 does not do these things in people: in the trials below it did not raise insulin, slow the stomach or change hunger. The newer weight-management treatments copy GLP-1, and are built to last days rather than minutes.
What does GLP-2 actually do in the body?
GLP-2 is what scientists call intestinotrophic: it feeds the growth of the intestine. Estall and Drucker's review describes how it makes the finger-like villi of the small bowel grow taller and the lining renew faster. It also tightens the seal between gut cells and increases blood flow to the gut after a meal. A taller, healthier lining has more surface to absorb food from.
That is why GLP-2 became a treatment, though for a condition most people never hear of. Short bowel syndrome happens when surgery, injury or disease has removed a long stretch of small intestine. The remaining gut cannot absorb enough food or water, and many patients depend on nutrition fed through a vein. Treatments built on GLP-2 help the gut that is left absorb more, so some patients need fewer of those feeds.
There is a newer line of interest too. Pálsson and colleagues point out that obesity tends to come with a leakier gut barrier, which lets fragments of gut bacteria slip into the blood. GLP-2 firms up that barrier in animal studies. Whether that helps people with obesity is still an open question, taken up further down.
Does GLP-2 reduce appetite or help with weight loss?
In people, the answer so far is no. Sørensen and colleagues ran GLP-2 into the veins of 18 healthy young adults for four and a half hours, then served them as many sandwiches as they wanted. Hunger, fullness, how good the food tasted and how much they ate were all the same as on the placebo day.
Schmidt and colleagues at the Karolinska Institutet tested the stomach directly. They used a scan that tracks a meal leaving the stomach. Even at high GLP-2 levels, the stomach emptied on the usual schedule and hunger after the meal did not change. GLP-1, given the same way in other studies, slows the stomach clearly.
Animal work tells a different story, which is where some of the online confusion starts. Ali and colleagues in Northern Ireland gave both hormones to mice and found that each suppressed appetite and improved sugar handling. Only GLP-1 pushed the pancreas to release more insulin, though. Mouse results often fail to carry over to people, and for GLP-2 the human appetite trials have so far come back flat. Claims online that GLP-2 burns fat tend to lean on animal results like these.
How long do GLP-1 and GLP-2 last in the blood?
Only a few minutes each. An enzyme in the blood called DPP-4 clips two amino acids off the front of each hormone, and the trimmed version barely works. Hartmann and colleagues tracked GLP-2 in healthy Danish volunteers. After a 500-calorie meal, only about 57% of the GLP-2 in their blood was still whole. When they infused pure GLP-2, half of it was gone in about seven minutes.
GLP-1 meets the same enzyme. So the GLP-1 from your breakfast does most of its work near the gut and the liver, and mostly within the first hour or two. That short lifespan is what treatment designers change. Swap a few building blocks so DPP-4 cannot get a grip, or tie the hormone to a carrier that keeps it circulating, and a signal that lasted minutes can last days.
You cannot stretch your own GLP-1 that far with food. What you can change is how strongly each meal triggers it. Start with protein, a bowl of curd or a katori of dal, and get vegetables in before the rice. Those habits have the most evidence, and the GLP-1 natural sources page under Read next goes through it. No study so far has shown a food raising GLP-2 enough to affect weight.
Why are scientists studying GLP-1 and GLP-2 together?
Search patent records and you will find dozens of filings for single molecules that act on both the GLP-1 and the GLP-2 receptor. That surprises people who have just read that GLP-2 does nothing for hunger. The interest is in the gut wall, and in inflammation.
Pálsson and colleagues in Copenhagen set out the idea. Obesity tends to come with a leakier gut barrier, so fragments of gut bacteria seep into the blood and keep a low-grade inflammation going. That inflammation feeds fatty liver and insulin resistance. GLP-1 action brings food intake down; GLP-2 action might seal the barrier. In obese mice and rats GLP-2 has a strong anti-inflammatory effect. Trials of combined treatments in people are at an early stage, and none has yet shown an added benefit.
Bone is the second reason. After a meal, the breakdown of old bone slows for a few hours, and gut hormones seem to carry that signal. Longo and colleagues reviewed this so-called gut-bone axis. Hansen's group then infused the hormones one at a time into ten adults with type 2 diabetes. GLP-2 on its own lowered a marker of new bone formation. GLP-1, GLP-2 and a third gut hormone, GIP, given together, slowed bone breakdown about as much as drinking glucose did. Anyone designing a treatment that takes off a lot of weight has reason to watch those numbers.
What happens to muscle when weight comes off on GLP-1 treatment?
Rekha's other question was about her sister-in-law. She has lost a lot of weight in six months on her GLP-1-based treatment. Now the stairs to her second-floor flat leave her thighs shaking. Was that the treatment, Rekha asked, or the weight loss?
Mostly it is the weight loss. Any route to a lighter body takes some lean tissue along with the fat. Laverde and colleagues pooled seven randomised trials, 821 participants in all, on GLP-1-based therapy at weight-management strength. Lean mass fell about 1.7 kg more than on placebo. Fat fell much further, so lean tissue still made up a larger share of the body at the end. Woźniak and colleagues saw the same in adults without diabetes.
Both groups closed with the same advice: eat enough protein and train. For the sister-in-law that means dal, curd, paneer or eggs at every meal, because most vegetarian thalis run short. It also means two short strength sessions a week, even chair squats and wall push-ups at home.
Rekha's sister-in-law wanted a smaller dress size and got weaker legs with it. Metaboliq plans start from the other end. The target is to lose up to 20% of body weight and keep the muscle, so the doctor reads the blood report and sets protein and strength work in week one.